RVTY Stock Analysis — Revvity
Sector: Healthcare
AI Verdict
Revvity trades at 20.3x next year's earnings while expected to grow EPS by 40.1%, which is cheap for the growth you're getting if its sticky diagnostics moat delivers as promised.
Competitive Moat
Revvity specializes in life sciences and diagnostics, with a defensible position built on proprietary assay technologies and deep integration into pharma and clinical research workflows. Its recurring revenue from consumables and long-term research contracts creates a sticky customer base that is hard for competitors to dislodge.
Summary
Revvity is on watch for its sharp 40.1% forward EPS growth expectation paired with a falling P/E.
Where It Stands
The stock is up 28.53% over the past year, trades at 20.3x next year's earnings versus the healthcare median of 22x, and its RSI of 62.9 is just below the elevated zone.
Key Metrics
- RSI: 62.9 — Near Overbought
- Trailing P/E: 28.4x
- Forward P/E: 20.3x
- PEG Ratio: 0.71
- Earnings Growth: +0.4%
- Revenue Growth: +0.0%
- Market Cap: $13.2B
- Dividend Yield: 0.00%
- 1-Year Return: 28.53%
- 52-Week High: $118.30
- 52-Week Low: $81.22
Analyst Consensus
13 Buy · 12 Hold · 0 Sell (25 analysts)
Bull Case
With analysts forecasting 40.1% EPS growth and a forward P/E of 20.3x, you're paying less than the sector median for much faster-than-average earnings acceleration.
Bear Case
If the forward P/E reverts to the sector median of 22x without delivering on the 40.1% EPS growth, the stock could see a pullback, especially with the RSI already at 62.9.
Catalyst to Watch
Watch for quarterly earnings updates—any miss on the 40.1% EPS growth target could quickly compress the multiple.